Chemoprevention of 1,2-dimethylhydrazine-induced colonic preneoplastic lesions in Fischer rats by 6-methylsulfinylhexyl isothiocyanate, a wasabi derivative. 2010

Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
Department of Tumor Pathology, Graduate School of Medicine, Gifu University, Gifu 501-1194.

The preventive effects of dietary exposure to a wasabi derivative 6-methylsulfinylhexyl isothiocyanate (6-MSITC) during the initiation and post-initiation phases on the development of 1,2-dimethylhydrazine (DMH)-induced colonic aberrant crypt foci (ACF), and β-catenin-accumulated crypts (BCAC) were investigated in male F344 rats. To induce ACF and BCAC, rats were given four weekly subcutaneous injections of DMH (40 mg/kg body weight). The rats also received diets containing 200 or 400 ppm 6-MSITC during the initiation or post-initiation phases. The experiment was terminated 12 weeks after the start. DMH exposure produced a substantial number of ACF (323.8±69.7/colon) and BCAC (3.80±1.05/cm(2)) at the end of the study. Dietary administration of 6-MSITC at a dose of 400 ppm during the initiation phase caused a significant reduction in the total number of ACF (52% reduction, P<0.0001), larger ACF (4 or more crypt ACF) (58% reduction, P<0.001) and BCAC (76% reduction, P<0.00001). The dietary exposure to 6-MSITC significantly reduced the size (crypt multiplicity) of BCAC during both initiation and post-initiation treatment when compared to group 1 treated with DMH alone. Immunohistochemically, 6-MSITC administration lowered the proliferating cell nuclear antigen labeling index in ACF and BCAC. In addition, protein levels of hepatic cytochrome P-450 isozymes at 24 h after 6-MSITC exposure were significantly suppressed (P<0.01). The results indicated that 6-MSITC exerted chemopreventive effects in the present short-term colon carcinogenesis bioassay, through alterations in cell proliferation activity and drug metabolizing enzyme levels.

UI MeSH Term Description Entries

Related Publications

Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
January 2018, Toxicology and applied pharmacology,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
March 2003, Phytochemistry,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
October 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
November 1997, Cytotechnology,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
December 2000, Carcinogenesis,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
April 2018, Digestive diseases and sciences,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
October 1990, Biochimica et biophysica acta,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
December 1988, European journal of clinical investigation,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
February 2014, Human & experimental toxicology,
Toshiya Kuno, and Yoshinobu Hirose, and Yasuhiro Yamada, and Katsumi Imaida, and Kenjiro Tatematsu, and Yukio Mori, and Hideki Mori
January 2008, International journal of cancer,
Copied contents to your clipboard!